Phase II study of etoposide for carcinoma of the prostate

P. J. Walther, S. D. Williams, M. Troner, F. A. Greco, R. Birch, Lawrence Einhorn

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The treatment of prostate carcinoma with the epipodophyllotoxin derivative etoposide was studied in a multi-institutional phase II trial. An iv dose schedule of 130 mg/m2 daily for 3 days every 3 weeks was utilized. A total of 36 patients were evaluable; the observed total response was 3%. Moderate toxicity (predominantly myelosuppression) was seen utilizing this treatment schedule. It is concluded that etoposide possesses little single-agent therapeutic activity for prostate carcinoma.

Original languageEnglish (US)
Pages (from-to)771-772
Number of pages2
JournalCancer Treatment Reports
Volume70
Issue number6
StatePublished - 1986
Externally publishedYes

Fingerprint

Etoposide
Prostate
Carcinoma
Appointments and Schedules
Podophyllotoxin
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Walther, P. J., Williams, S. D., Troner, M., Greco, F. A., Birch, R., & Einhorn, L. (1986). Phase II study of etoposide for carcinoma of the prostate. Cancer Treatment Reports, 70(6), 771-772.

Phase II study of etoposide for carcinoma of the prostate. / Walther, P. J.; Williams, S. D.; Troner, M.; Greco, F. A.; Birch, R.; Einhorn, Lawrence.

In: Cancer Treatment Reports, Vol. 70, No. 6, 1986, p. 771-772.

Research output: Contribution to journalArticle

Walther, PJ, Williams, SD, Troner, M, Greco, FA, Birch, R & Einhorn, L 1986, 'Phase II study of etoposide for carcinoma of the prostate', Cancer Treatment Reports, vol. 70, no. 6, pp. 771-772.
Walther PJ, Williams SD, Troner M, Greco FA, Birch R, Einhorn L. Phase II study of etoposide for carcinoma of the prostate. Cancer Treatment Reports. 1986;70(6):771-772.
Walther, P. J. ; Williams, S. D. ; Troner, M. ; Greco, F. A. ; Birch, R. ; Einhorn, Lawrence. / Phase II study of etoposide for carcinoma of the prostate. In: Cancer Treatment Reports. 1986 ; Vol. 70, No. 6. pp. 771-772.
@article{d5875657fc1d42599afe49fc332bc846,
title = "Phase II study of etoposide for carcinoma of the prostate",
abstract = "The treatment of prostate carcinoma with the epipodophyllotoxin derivative etoposide was studied in a multi-institutional phase II trial. An iv dose schedule of 130 mg/m2 daily for 3 days every 3 weeks was utilized. A total of 36 patients were evaluable; the observed total response was 3{\%}. Moderate toxicity (predominantly myelosuppression) was seen utilizing this treatment schedule. It is concluded that etoposide possesses little single-agent therapeutic activity for prostate carcinoma.",
author = "Walther, {P. J.} and Williams, {S. D.} and M. Troner and Greco, {F. A.} and R. Birch and Lawrence Einhorn",
year = "1986",
language = "English (US)",
volume = "70",
pages = "771--772",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Phase II study of etoposide for carcinoma of the prostate

AU - Walther, P. J.

AU - Williams, S. D.

AU - Troner, M.

AU - Greco, F. A.

AU - Birch, R.

AU - Einhorn, Lawrence

PY - 1986

Y1 - 1986

N2 - The treatment of prostate carcinoma with the epipodophyllotoxin derivative etoposide was studied in a multi-institutional phase II trial. An iv dose schedule of 130 mg/m2 daily for 3 days every 3 weeks was utilized. A total of 36 patients were evaluable; the observed total response was 3%. Moderate toxicity (predominantly myelosuppression) was seen utilizing this treatment schedule. It is concluded that etoposide possesses little single-agent therapeutic activity for prostate carcinoma.

AB - The treatment of prostate carcinoma with the epipodophyllotoxin derivative etoposide was studied in a multi-institutional phase II trial. An iv dose schedule of 130 mg/m2 daily for 3 days every 3 weeks was utilized. A total of 36 patients were evaluable; the observed total response was 3%. Moderate toxicity (predominantly myelosuppression) was seen utilizing this treatment schedule. It is concluded that etoposide possesses little single-agent therapeutic activity for prostate carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0022521883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022521883&partnerID=8YFLogxK

M3 - Article

C2 - 3524825

AN - SCOPUS:0022521883

VL - 70

SP - 771

EP - 772

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -